These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Industry warily eyes new Medicare drug plan. Vastag B Nat Biotechnol; 2006 Feb; 24(2):120. PubMed ID: 16465141 [No Abstract] [Full Text] [Related]
45. Is there balm in Gilead? Jacobs T Nat Biotechnol; 2006 Dec; 24(12):1478. PubMed ID: 17160040 [No Abstract] [Full Text] [Related]
46. The production capacity bottleneck. De Keyser JL Nat Biotechnol; 2001 Aug; 19(8):715. PubMed ID: 11479555 [No Abstract] [Full Text] [Related]
47. Swooping for biotech. Wadman M Nature; 2005 Sep; 437(7058):475. PubMed ID: 16177760 [No Abstract] [Full Text] [Related]
48. How the street sees biotech. Lashinsky A Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576 [No Abstract] [Full Text] [Related]
49. Cetus and Chiron merge. Gershon D Nature; 1991 Aug; 352(6334):364. PubMed ID: 1861710 [No Abstract] [Full Text] [Related]
50. Sanofi Aventis grooms its ranks for biotech partnering. Moran N Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645 [No Abstract] [Full Text] [Related]
51. Value creation and sharing among universities, biotechnology and pharma. Edwards MG; Murray F; Yu R Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145 [No Abstract] [Full Text] [Related]
52. Biotech acquisitions by big pharma: why and what is next. Malik NN Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004 [TBL] [Abstract][Full Text] [Related]